BNR 6-K 2022 - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OFFOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2022

Commission File Number: 001-39316

BURNING ROCK BIOTECH LIMITED

(Registrant’s Name)

No.5 XingdaoRing Road North, International Bio Island

Guangzhou, Guangdong

People’s Republic of China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

EXHIBIT INDEX

Number	Description of Document
99.1	Press release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Burning Rock Biotech Limited
	By:	/s/ Leo Li
	Name:	Leo Li
	Title:	Chief Financial Officer
Date: August 31, 2022

EX-99.1

Exhibit 99.1

Burning Rock Reports Second Quarter 2022 Financial Results

GUANGZHOU, China, August 31, 2022—Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2022.

Recent Business Updates

•	Therapy Selection and Minimal Residual Disease (MRD)

In-hospital and MRD driving growth uplift, but patient volumes negatively impacted by Covid related restrictions.

•	For the in-hospital channel, we experienced severe Covid related impact<br>in Shanghai and to a lesser extent in Beijing. However, other regions combined grew over 60% year-over-year in the second quarter of 2022 in terms of testing volume;
•	For the central-lab channel, new product sales contributed 7% of the<br>central laboratory segmental revenues in the second quarter of 2022.
---	---
•	Early Detection
---	---
•	PROMISE study (2,035 participants) for 9-cancer test completed, reading<br>out at European Society for Medical Oncology (ESMO) Congress 2022 in Sepetember;
---	---
•	PREVENT study, China’s first multi-cancer prospective interventional study, involving 12,500 participants,<br>launched in the second quarter of 2022.
---	---
•	Pharma Services
---	---
•	Continued revenue growth, with 166.6% revenue growth year-on-year in the second quarter of 2022. Pharma service contract backlog continues to build rapidly;
---	---
•	The total value of new contracts we entered into amounted to RMB158 million from January to July 2022,<br>representing approximately 49% increase from the same period of 2021.
---	---

Second Quarter 2022 Financial Results

Revenues were RMB130.8 million (US$19.5 million) for the three months ended June 30, 2022, representing a 2.8% increase from RMB127.3 million for the same period in 2021.

•	Revenue generated from central laboratory business was RMB78.6 million (US$11.7 million) for the three<br>months ended June 30, 2022, representing a 1.8% decrease from RMB80.0 million for the same period in 2021. Covid related negative impact was partially offset by growth from newly launched products. Sequentially, central laboratory revenues<br>increased by 5.9% compared to the first quarter of 2022, driven by new product launches.
•	Revenue generated from in-hospital business was RMB34.2 million<br>(US$5.1 million) for the three months ended June 30, 2022, representing a 15.6% decrease from RMB40.5 million for the same period in 2021, primarily attributable to severe declines in testing volume in Shanghai due to Covid-19 lockdown, and to a lesser extent, declines in testing volume in Beijing; other regions outside of Shanghai and Beijing showed strong growth.
---	---
•	Revenue generated from pharma research and development services was RMB18.1 million (US$2.7 million) for the<br>three months ended June 30, 2022, representing a 166.6% increase from RMB6.8 million for the same period in 2021, primarily attributable to the increased services performed for our pharma customers as we executed our contracted pharma<br>service projects.
---	---

Cost of revenues **** was RMB48.2 million (US$7.2 million) for the three months ended June 30, 2022, representing a 30.2% increase from RMB37.0 million for the same period in 2021, primarily due to the increased depreciation in relation to our new laboratory and inventory write downs.

Gross profit **** was RMB82.6 million (US$12.3 million) for the three months ended June 30, 2022, representing a 8.5% decrease from RMB90.2 million for the same period in 2021. Gross margin was 63.1% for the three months ended June 30, 2022, which decreased from 70.9% for the same period in 2021, primarily due to increased depreciation in relation to our new laboratory and inventory write downs.

Non-GAAP gross profit was RMB90.9 million (US$13.6 million) for the three months ended June 30, 2022, representing a 0.3% increase from RMB90.7 million for the same period in 2021. Non-GAAP gross margin was 69.5% for the three months ended June 30, 2022, compared to 71.2% for the same period in 2021 primarily due to a 0.7% decrease of gross margin resulting from increase of RMB0.9 million in inventory write down.

Operating expenses were RMB348.1 million (US$52.0 million) for the three months ended June 30, 2022, representing a 19.1% increase from RMB292.3 million for the same period in 2021.

•	Research and development expenses were RMB92.1 million (US$13.8 million) for the three months ended<br>June 30, 2022, representing a 14.8% decrease from RMB108.1 million for the same period in 2021, primarily due to a decrease in research and development project cost and a decrease in share-based compensation.
•	Selling and marketing expenses were RMB105.6 million (US$15.8 million) for the three months ended<br>June 30, 2022, representing a 55.2% increase from RMB68.1 million for the same period in 2021, primarily due to (i) an increase in staff cost resulted from increase in headcount; (ii) an increase in marketing related<br>expenditures, such as entertainment expense, conference fee and marketing expense and (iii) an increase in amortized expense on modification for Employee Share Incentive Plan. Sequentially, headcount cost, excluding one-off items such as organizational restructuring expenses, decreased in the second quarter of 2022 compared to the first quarter.
---	---
•	General and administrative expenses were RMB150.3 million (US$22.4 million) for the three months ended<br>June 30, 2022, representing a 29.4% increase from RMB116.1 million for the same period in 2021, primarily due to (i) an increase in depreciation expenses for new office space; (ii) an increase in amortized expense on modification<br>for Employee Share Incentive Plan.
---	---

Net loss was RMB262.1 million (US$39.1 million) for the three months ended June 30, 2022, compared to RMB203.7 million for the same period in 2021.

Net cash used in operating activities was RMB109.3 million (US$16.3 million) for the three months ended June 30, 2022, compared to RMB119.0 million for the same period in 2021. The balance of cash, cash equivalents, restricted cash and short-term investments was RMB1,153.1 million (US$172.1 million) as of June 30, 2022.

2022 Financial Guidance

Second quarter business volumes have been significantly impacted by Covid related restrictions, with severe volume drops in Shanghai and Beijing; however, pharma service revenues, new products and the in-hospital business outside of Shanghai and Beijing have shown strong growth momentum. Burning Rock therefore retains its full year 2022 revenue guidance of approximately RMB620 million (US$92.6 million) for now, and would like to highlight the risks of further Covid related impact in the second half of 2022 which is beyond the Company’s control and inherently difficult to forecast.

ShareRepurchases

Further to the Company’s announcement on June 21, 2022 of a US$10 million share repurchase program, we are pleased to announce that the repurchase program has been completed in full. The Company has repurchased a total of 3,023,138 Class A ordinary shares in the form of ADSs under the share repurchase program. The repurchased shares will be retained as treasury shares and have not been taken out of the calculation of loss per share for the second quarter 2022 financial results.

Conference CallInformation

Burning Rock will host a conference call to discuss the second quarter 2022 financial results at 8:30 a.m. U.S. Eastern Time (8:30 p.m. Hong Kong time) on August 31, 2022.

Please register in advance of the conference using the link provided below and dial in 15 minutes prior to the call, using participant dial-in numbers and unique registrant ID which would be provided upon registering.

PRE-REGISTER LINK: https://register.vevent.com/register/BI1f6043e15b804286b8c6f5db40d78456. Additionally, a live and archived webcast of the conference call will also be available on the company’s investor relations website at http://ir.brbiotech.com or through link https://edge.media-server.com/mmc/p/57gam4s5.

A replay of the webcast will be available for 12 months via the same link above.

About Burning Rock

Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.

For more information about Burning Rock, please visit: ir.brbiotech.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

Non-GAAP Measures

In evaluating the business, the company considers and uses non-GAAP measures, such as non-GAAP gross profit and non-GAAP gross margin, as supplemental measures to review and assess operating performance. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The company defines non-GAAP gross profit as gross profit excluding depreciation and amortization. The company defines non-GAAP gross margin as gross margin excluding depreciation and amortization.

The company presents these non-GAAP financial measures because they are used by management to evaluate operating performance and formulate business plans. The company believe non-GAAP gross profit and non-GAAP gross margin excluding non-cash impact of depreciation and amortization reflect the company’s ongoing business operations in a manner that allows more meaningful period-to-period comparisons.

Contact: [email protected]

Selected Operating Data

	For the three months ended
	March 31,<br>2021		June 30,<br>2021		September 30,2021		December 31,<br>2021		March 31,2022		June 30,2022
Central Laboratory Channel:
Number of patients tested		7,716		8,155		7,808		8,235		7,743		8,060
Number of ordering physicians^(1)^		1,082		1,013		920		917		994		767
Number of ordering hospitals^(2)^		303		300		287		306		318		264
^(1)^	Represents physicians who on average order at least one test from us every month during a relevant period in<br>the central laboratory channel.
---	---
^(2)^	Represents hospitals whose residing physicians who on average order at least one test from us every month<br>during a relevant period in the central laboratory channel.
---	---
	As of
---	---	---	---	---	---	---	---	---	---	---	---	---
	March 31,<br>2021		June 30,<br>2021		September 30,2021		December 31,<br>2021		March 31,2022		June 30,2022
In-hospital Channel:
Pipeline partner hospitals^(1)^		22		22		24		23		24		25
Contracted partner hospitals^(2)^		32		34		34		41		41		43
Total number of partner hospitals	****	54	****	56	****	58	****	64	****	65	****	68
^(1)^	Refers to hospitals that are in the process of establishing in-hospital<br>laboratories, laboratory equipment procurement or installation, staff training or pilot testing using the Company’s products.
---	---
^(2)^	Refers to hospitals that have entered into contracts to purchase the Company’s products for use on a<br>recurring basis in their respective in-hospital laboratories the Company helped them establish. Kit revenue is generated from contracted hospitals.
---	---

Selected Financial Data

	For the three months ended
Revenues	March 31,<br>2021		June 30,<br>2021		September 30,2021		December 31,<br>2021		March 31,2022		June 30,2022
	(RMB in thousands)
Central laboratory channel		74,561		79,999		78,817		85,976		74,211		78,597
In-hospital channel		28,994		40,502		43,714		51,906		48,957		34,177
Pharma research and development channel		3,068		6,778		4,084		9,463		12,356		18,072
Total revenues	****	106,623	****	127,279	****	126,615	****	147,345	****	135,524	****	130,846
	For the three months ended
---	---	---	---	---	---	---	---	---	---	---	---	---
Gross profit	March 31,<br>2021		June 30,<br>2021		September 30,2021		December 31,<br>2021		March 31,2022		June 30,2022
	(RMB in thousands)
Central laboratory channel		55,212		58,681		58,387		65,985		50,574		57,575
In-hospital channel		20,070		29,426		31,111		34,194		33,396		20,012
Pharma research and development channel		1,658		2,124		2,098		5,200		3,610		5,015
Total gross profit	****	76,940	****	90,231	****	91,596	****	105,379	****	87,580	****	82,602
	For the three months ended
---	---	---	---	---	---	---	---	---	---	---	---	---	---	---
Share-based compensation expenses	March 31,<br>2021		June 30,<br>2021		September 30,2021			December 31,<br>2021			March 31,2022		June 30,2022
	(RMB in thousands)
Cost of revenues		339		406		267			492			365		441
Research and development expenses		22,404		20,825		(9,559	)		(4,033	)		12,299		11,923
Selling and marketing expenses		2,633		2,809		2,044			2,126			1,774		2,158
General and administrative expenses		59,382		59,369		60,803			62,126			65,715		62,615
Total share-based compensation expenses	****	84,758	****	83,409	****	53,555	****	****	60,711	****	****	80,153	****	77,137

Burning Rock Biotech Limited

Unaudited Condensed Statements of Comprehensive Loss

(in thousands, except for number of shares and per share data)

	For the three months ended
	March 31,<br>2021			June 30,<br>2021			September 30,2021			December 31,<br>2021			March 31,2022			June 30,2022			June 30,2022
	RMB			RMB			RMB			RMB			RMB			RMB			US
Revenues	****	106,623	****	****	127,279	****	****	126,615	****	****	147,345	****	****	135,524	****	****	130,846	****		****
Cost of revenues	****	(29,683	)	****	(37,048	)	****	(35,019	)	****	(41,966	)	****	(47,944	)	****	(48,244	)		)
Gross profit	****	76,940	****	****	90,231	****	****	91,596	****	****	105,379	****	****	87,580	****	****	82,602	****		****
Operating expenses:
Research and development expenses		(77,414	)		(108,071	)		(69,649	)		(112,724	)		(119,496	)		(92,112	)		)
Selling and marketing expenses		(55,130	)		(68,058	)		(76,687	)		(103,221	)		(89,211	)		(105,634	)		)
General and administrative expenses		(116,259	)		(116,130	)		(116,304	)		(141,563	)		(141,733	)		(150,316	)		)
Total operating expenses	****	(248,803	)	****	(292,259	)	****	(262,640	)	****	(357,508	)	****	(350,440	)	****	(348,062	)		)
Loss from operations	****	(171,863	)	****	(202,028	)	****	(171,044	)	****	(252,129	)	****	(262,860	)	****	(265,460	)		)
Interest income		787			681			958			1,031			1,832			2,685
Interest expenses		(510	)		(565	)		(367	)		(94	)		119			(29	)		)
Other income (expense), net		118			433			20			(372	)		298			127
Foreign exchange gain (loss), net		57			(560	)		380			(731	)		(777	)		624
Loss before income tax	****	(171,411	)	****	(202,039	)	****	(170,053	)	****	(252,295	)	****	(261,388	)	****	(262,053	)		)
Income tax (expenses) benefits		—			(1,626	)		(424	)		1,151			—			(84	)		)
Net loss	****	(171,411	)	****	(203,665	)	****	(170,477	)	****	(251,144	)	****	(261,388	)	****	(262,137	)		)
Net loss attributable to Burning Rock Biotech Limited’s shareholders		(171,411	)		(203,665	)		(170,477	)		(251,144	)		(261,388	)		(262,137	)		)
Net loss attributable to ordinary shareholders	****	(171,411	)	****	(203,665	)	****	(170,477	)	****	(251,144	)	****	(261,388	)	****	(262,137	)		)
Loss per share for class A and class B ordinary shares:
Class A ordinary shares - basic and diluted		(1.65	)		(1.96	)		(1.64	)		(2.40	)		(2.50	)		(2.50	)		)
Class B ordinary shares - basic and diluted		(1.65	)		(1.96	)		(1.64	)		(2.40	)		(2.50	)		(2.50	)		)
Weighted average shares outstanding used in loss per share computation:
Class A ordinary shares - basic and diluted		86,721,263			86,764,260			86,908,975			87,128,297			87,179,752			87,532,539
Class B ordinary shares - basic and diluted		17,324,848			17,324,848			17,324,848			17,324,848			17,324,848			17,324,848
Other comprehensive income (loss), net of tax of nil:
Foreign currency translation adjustments		14,080			(34,980	)		6,146			(24,726	)		(3,065	)		29,715
Total comprehensive loss	****	(157,331	)	****	(238,645	)	****	(164,331	)	****	(275,870	)	****	(264,453	)	****	(232,422	)		)
Total comprehensive loss attributable to Burning Rock Biotech Limited’sshareholders	****	(157,331	)	****	(238,645	)	****	(164,331	)	****	(275,870	)	****	(264,453	)	****	(232,422	)		)

All values are in US Dollars.

Burning Rock Biotech Limited

Unaudited Condensed Statements of Comprehensive Loss

(in thousands, except for number of shares and per share data)

	For the six months ended
	June 30,<br>2021			June 30,<br>2022			June 30,2022
	RMB			RMB			US
Revenues	****	233,902	****	****	266,370	****		****
Cost of revenues	****	(66,731	)	****	(96,188	)		)
Gross profit	****	167,171	****	****	170,182	****		****
Operating expenses:
Research and development expenses		(185,485	)		(211,608	)		)
Selling and marketing expenses		(123,188	)		(194,845	)		)
General and administrative expenses		(232,389	)		(292,049	)		)
Total operating expenses	****	(541,062	)	****	(698,502	)		)
Loss from operations	****	(373,891	)	****	(528,320	)		)
Interest income		1,468			4,517
Interest expenses		(1,075	)		90
Other income, net		551			425
Foreign exchange loss, net		(503	)		(153	)		)
Loss before income tax	****	(373,450	)	****	(523,441	)		)
Income tax expenses		(1,626	)		(84	)		)
Net loss	****	(375,076	)	****	(523,525	)		)
Net loss attributable to Burning Rock Biotech Limited’s shareholders	****	(375,076	)	****	(523,525	)		)
Net loss attributable to ordinary shareholders	****	(375,076	)	****	(523,525	)		)
Loss per share for class A and class B ordinary shares:
Class A ordinary shares - basic and diluted		(3.60	)		(5.00	)		)
Class B ordinary shares - basic and diluted		(3.60	)		(5.00	)		)
Weighted average shares outstanding used in loss per share computation:
Class A ordinary shares - basic and diluted		86,742,880			87,357,120
Class B ordinary shares - basic and diluted		17,324,848			17,324,848
Other comprehensive income (loss), net of tax of nil:
Foreign currency translation adjustments		(20,900	)		26,650
Total comprehensive loss	****	(395,976	)	****	(496,875	)		)
Total comprehensive loss attributable to Burning Rock Biotech Limited’sshareholders	****	(395,976	)	****	(496,875	)		)

All values are in US Dollars.

Burning Rock Biotech Limited

Unaudited Condensed Consolidated Balance Sheets

(In thousands)

	As of
	December 31,2021		June 30,<br>2022		June 30,2022
	RMB		RMB		US
ASSETS
Current assets:
Cash and cash equivalents		1,431,317		1,148,597
Restricted cash		7,795		4,453
Short-term investments		63,757		—
Accounts receivable, net		92,197		100,960
Contract assets, net		42,391		44,593
Inventories, net		123,210		129,637
Prepayments and other current assets, net		60,279		34,845
Total current assets	****	1,820,946	****	1,463,085
Non-current assets:
Equity method investment		910		733
Convertible note receivable		—		5,000
Property and equipment, net		325,438		301,249
Operating<br>right-of-use assets		81,007		66,655
Intangible assets, net		5,150		3,354
Other non-current assets		45,136		21,198
Total non-current assets	****	457,641	****	398,189
TOTAL ASSETS	****	2,278,587	****	1,861,274

All values are in US Dollars.

Burning Rock Biotech Limited

Unaudited Condensed Consolidated Balance Sheets (Continued)

(in thousands)

	As of
	December 31,2021			June 30,<br>2022			June 30,2022
	RMB			RMB			US
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable		63,080			56,495
Deferred revenue		142,871			163,093
Accrued liabilities and other current liabilities		127,892			98,435
Customer deposits		972			1,052
Short-term borrowing		2,370			2,370
Current portion of operating lease liabilities		34,999			38,005
Total current liabilities	****	372,184	****	****	359,450	****		****
Non-current liabilities:
Non-current portion of operating lease<br>liabilities		49,316			32,349
Other non-current liabilities		11,776			37,242
Total non-current liabilities	****	61,092	****	****	69,591	****		****
TOTAL LIABILITIES	****	433,276	****	****	429,041	****		****
Shareholders’ equity:
Class A ordinary shares		116			116
Class B ordinary shares		21			21
Additional paid-in capital		4,280,956			4,431,603
Contra equity-prepayment for equity forward		—			(66,850	)		)
Accumulated deficits		(2,228,713	)		(2,752,238	)		)
Accumulated other comprehensive loss		(207,069	)		(180,419	)		)
Total shareholders’ equity	****	1,845,311	****	****	1,432,233	****		****
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	****	2,278,587	****	****	1,861,274	****		****

All values are in US Dollars.

Burning Rock Biotech Limited

Unaudited Condensed Statements of Cash Flows

(in thousands)

	For the three months ended
	June 30, 2021			June 30, 2022			June 30, 2022
	RMB			RMB			US
Net cash used in operating activities		(118,998	)		(109,274	)		)
Net cash (used in) generated from investing activities		(67,577	)		30,729
Net cash used in financing activities		(8,961	)		(69,559	)		)
Effect of exchange rate on cash, cash equivalents and restricted cash		(34,085	)		26,279
Net decrease in cash, cash equivalents and restricted cash	****	(229,621	)	****	(121,825	)		)
Cash, cash equivalents and restricted cash at the beginning of period		2,112,886			1,274,875
Cash, cash equivalents and restricted cash at the end of period	****	1,883,265	****	****	1,153,050	****		****

All values are in US Dollars.

	For the six months ended
	June 30, 2021			June 30, 2022			June 30, 2022
	RMB			RMB			US
Net cash used in operating activities		(232,143	)		(253,634	)		)
Net cash generated from investing activities		220,752			17,718
Net cash used in financing activities		(13,123	)		(73,493	)		)
Effect of exchange rate on cash, cash equivalents and restricted cash		(17,427	)		23,347
Net decrease in cash, cash equivalents and restricted cash	****	(41,941	)	****	(286,062	)		)
Cash, cash equivalents and restricted cash at the beginning of period		1,925,206			1,439,112
Cash, cash equivalents and restricted cash at the end of period	****	1,883,265	****	****	1,153,050	****		****

All values are in US Dollars.

Burning Rock Biotech Limited

Reconciliations of GAAP and Non-GAAP Results

	For the three months ended
	March 31,<br>2021			June 30,<br>2021			September 30,2021			December 31,<br>2021			March 31,2022			June 30,2022
	(RMB in thousands)
Gross profit:
Central laboratory channel		55,212			58,681			58,387			65,985			50,574			57,575
In-hospital channel		20,070			29,426			31,111			34,194			33,396			20,012
Pharma research and development channel		1,658			2,124			2,098			5,200			3,610			5,015
Total gross profit	****	76,940	****	****	90,231	****	****	91,596	****	****	105,379	****	****	87,580	****	****	82,602	****
Add: depreciation and amortization:
Central laboratory channel		117			284			1,254			995			2,553			2,545
In-hospital channel		79			113			109			130			93			1,428
Pharma research and development channel		10			40			19			856			2,493			4,327
Total depreciation and amortization included in cost of revenues	****	206	****	****	437	****	****	1,382	****	****	1,981	****	****	5,139	****	****	8,300	****
Non-GAAP gross profit:
Central laboratory channel		55,329			58,965			59,641			66,980			53,127			60,120
In-hospital channel		20,149			29,539			31,220			34,324			33,489			21,440
Pharma research and development channel		1,668			2,164			2,117			6,056			6,103			9,342
Total non-GAAP gross profit	****	77,146	****	****	90,668	****	****	92,978	****	****	107,360	****	****	92,719	****	****	90,902	****
Non-GAAP gross margin:
Central laboratory channel		74.2	%		73.7	%		75.7	%		77.9	%		71.6	%		76.5	%
In-hospital channel		69.5	%		72.9	%		71.4	%		66.1	%		68.4	%		62.7	%
Pharma research and development channel		54.4	%		31.9	%		51.8	%		64.0	%		49.4	%		51.7	%
Total non-GAAP gross margin	****	72.4	%	****	71.2	%	****	73.4	%	****	72.9	%	****	68.4	%	****	69.5	%